February 1, 2024 A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology...
November 3, 2018 D-RSC and PSTC presented “Biomarkers for Muscle Diseases” poster at the 2018 MDA Clinical Conference
April 16, 2018 Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path
January 22, 2018 Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort
January 22, 2018 Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (E
October 26, 2017 226th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy
May 22, 2017 miR-122 An Exploratory Biomarker of Liver Injury: An Industry Perspective on the State of the Science and Experiences Pre-Clinically and Clinically The Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) hosted a webinar focused on providing an industry pers
February 24, 2017 Biomarker Qualification: Collaboration, Strategy, and Implementation Biomarker Qualification: Collaboration, Strategy, and Implementation Webinar February 24th, 2017 Presenter: John Michael Sauer, Ph
